Deulorlatinib vs Iruplinalkib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK;ROS1 · full Non-Small Cell Lung Cancer pipeline

Deulorlatinib

Developed by Shenzhen TargetRx and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Iruplinalkib

Marketed by Qilu Pharmaceutical

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04632758 · Phase 3 · status unknown

This open-label, randomized phase 3 trial assigned 292 patients with ALK-positive advanced non-small cell lung cancer who had not had an ALK inhibitor to iruplinalkib (WX-0593) or crizotinib. Patients and doctors knew which drug was given, but progression was assessed by an independent review committee. At the planned interim analysis, progression-free survival, the primary measure, was significantly longer with iruplinalkib (median 27.7 vs 14.6 months; hazard ratio 0.34; p<0.0001), so the result is met. The figures come from the peer-reviewed report of the trial in the Journal of Thoracic Oncology.

Next expected readout: March 2027 · NCT05765877 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (from randomization until firstly recorded disease progression or death (whichever occurs earlier), or to the date that the last patients observed for 12 months): INSPIRE interim analysis, primary, IRC-assessed progression-free survival: median 27.7 months with iruplinalkib (WX-0593) vs 14.6 months with crizotinib; hazard ratio 0.34 (98.02% CI 0.23 to 0.52; p<0.0001), met. (met)

Result source: NCT04632758

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDeulorlatinibIruplinalkib
PFS, median—Trial running · NCT06082635—Not reported
OS, median—Trial running · NCT06082635—Not reported
ORR—Trial running · NCT06082635—Not reported
Duration of response, median—Trial running · NCT06082635—Not reported

PFS, median

Deulorlatinib
—Trial running · NCT06082635
Iruplinalkib
—Not reported

OS, median

Deulorlatinib
—Trial running · NCT06082635
Iruplinalkib
—Not reported

ORR

Deulorlatinib
—Trial running · NCT06082635
Iruplinalkib
—Not reported

Duration of response, median

Deulorlatinib
—Trial running · NCT06082635
Iruplinalkib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Deulorlatinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Iruplinalkib
INSPIRE interim analysis, primary, IRC-assessed progression-free survival: median 27.7 months with iruplinalkib (WX-0593) vs 14.6 months with crizotinib; hazard ratio 0.34 (98.02% CI 0.23 to 0.52; p<0.0001), met. NCT04632758 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Deulorlatinib's landscape · Iruplinalkib's landscape